S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Tenaya Therapeutics Stock Forecast, Price & News

0.00 (0.00%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
63,578 shs
Average Volume
175,726 shs
Market Capitalization
$811.17 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TNYA News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Tenaya Therapeutics logo

About Tenaya Therapeutics

Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company's product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$7.36 per share


Net Income
$-38.40 million
Pretax Margin




Free Float
Market Cap
$811.17 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.70 out of 5 stars

Medical Sector

921st out of 1,392 stocks

Biological Products, Except Diagnostic Industry

138th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Tenaya Therapeutics (NASDAQ:TNYA) Frequently Asked Questions

Is Tenaya Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tenaya Therapeutics stock.
View analyst ratings for Tenaya Therapeutics
or view top-rated stocks.

When is Tenaya Therapeutics' next earnings date?

Tenaya Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Tenaya Therapeutics

How were Tenaya Therapeutics' earnings last quarter?

Tenaya Therapeutics Inc (NASDAQ:TNYA) issued its earnings results on Wednesday, November, 10th. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.20.
View Tenaya Therapeutics' earnings history

What price target have analysts set for TNYA?

4 brokers have issued 12-month price targets for Tenaya Therapeutics' shares. Their forecasts range from $31.00 to $40.00. On average, they anticipate Tenaya Therapeutics' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 83.2% from the stock's current price.
View analysts' price targets for Tenaya Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Tenaya Therapeutics IPO?

(TNYA) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

What is Tenaya Therapeutics' stock symbol?

Tenaya Therapeutics trades on the NASDAQ under the ticker symbol "TNYA."

When does the company's lock-up period expire?

Tenaya Therapeutics' lock-up period expires on Wednesday, January 26th. Tenaya Therapeutics had issued 12,000,000 shares in its public offering on July 30th. The total size of the offering was $180,000,000 based on an initial share price of $15.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Tenaya Therapeutics' major shareholders?

Tenaya Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Casdin Capital LLC (8.69%), RA Capital Management L.P. (8.60%), RTW Investments LP (5.96%), BlackRock Inc. (3.92%), Harvard Management Co. Inc. (1.63%) and Commodore Capital LP (1.24%).

Which institutional investors are buying Tenaya Therapeutics stock?

TNYA stock was purchased by a variety of institutional investors in the last quarter, including Casdin Capital LLC, RA Capital Management L.P., RTW Investments LP, BlackRock Inc., Harvard Management Co. Inc., Commodore Capital LP, StepStone Group LP, and Trustees of Columbia University in the City of New York.

How do I buy shares of Tenaya Therapeutics?

Shares of TNYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenaya Therapeutics' stock price today?

One share of TNYA stock can currently be purchased for approximately $19.65.

How much money does Tenaya Therapeutics make?

Tenaya Therapeutics has a market capitalization of $811.17 million.

How many employees does Tenaya Therapeutics have?

Tenaya Therapeutics employs 2,021 workers across the globe.

What is Tenaya Therapeutics' official website?

The official website for Tenaya Therapeutics is www.tenayatherapeutics.com.

How can I contact Tenaya Therapeutics?

The company can be reached via phone at 415-865-2066.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.